公开(公告)号：US06218404B1

公开(公告)日：2001-04-17

申请号：US09091592

申请日：1998-09-16

申请人： Christopher F. Bigge ,  Gian Luca Araldi ,  Sui Xiong Cai ,  Anthony P. Guzikowski ,  Donald Lamunyon ,  Nancy F. Lan ,  Zhang-Lin Zhou ,  John F. W. Keana

发明人： Christopher F. Bigge ,  Gian Luca Araldi ,  Sui Xiong Cai ,  Anthony P. Guzikowski ,  Donald Lamunyon ,  Nancy F. Lan ,  Zhang-Lin Zhou ,  John F. W. Keana

IPC分类号： C07D21106

CPC分类号： C07D239/06 ,  C07D211/14 ,  C07D211/18 ,  C07D217/04 ,  C07D221/16 ,  C07D221/28 ,  C07D233/26 ,  C07D451/06 ,  C07D471/04

摘要： The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neuro-degenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

摘要翻译： 本发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风，缺血，CNS创伤，低血糖和手术相关的神经元损失的用途，以及治疗神经变性疾病，包括阿尔茨海默病，肌萎缩性侧索硬化，亨廷顿舞蹈病 治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑症，精神病，抽搐，氨基糖苷类抗生素诱发的听力损失，偏头痛，慢性疼痛，帕金森病，青光眼，CMV视网膜炎，尿失禁 ，阿片类药物耐受或戒断，诱导麻醉以及增强认知功能。

公开(公告)号：US06534522B2

公开(公告)日：2003-03-18

申请号：US09779024

申请日：2001-02-07

申请人： Christopher F. Bigge ,  Gian Luca Araldi ,  Sui Xiong Cai ,  Anthony P. Guzikowski ,  Donald Lamunyon ,  Nancy C. Lan ,  Zhang-Lin Zhou ,  John F. W. Keana

发明人： Christopher F. Bigge ,  Gian Luca Araldi ,  Sui Xiong Cai ,  Anthony P. Guzikowski ,  Donald Lamunyon ,  Nancy C. Lan ,  Zhang-Lin Zhou ,  John F. W. Keana

IPC分类号： C07D40112

CPC分类号： C07D239/06 ,  C07D211/14 ,  C07D211/18 ,  C07D217/04 ,  C07D221/16 ,  C07D221/28 ,  C07D233/26 ,  C07D451/06 ,  C07D471/04

摘要： The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

摘要翻译： 本发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风，缺血，CNS创伤，低血糖和手术相关的神经元损失的用途，以及治疗神经变性疾病，包括阿尔茨海默病，肌萎缩性侧索硬化，亨廷顿病和 唐氏综合征，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑症，精神病，抽搐，氨基糖苷类抗生素诱发的听力损失，偏头痛，慢性疼痛，帕金森病，青光眼，CMV视网膜炎，尿失禁，阿片样物质 容忍或戒断，诱导麻醉以及增强认知。